Is testing for antiphosphatidylethanolamine antibodies clinically useful?

Current Rheumatology Reports

Volumn 13, Issue 1, 2011, Pages 81-85

  Sanmarco, Marielle ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Antiphosphatidylethanolamine antibodies; Antiphospholipid syndrome; Phosphatidylethanolamine; Recurrent fetal losses; Thrombosis

Indexed keywords

ACTIVATED PROTEIN C; ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; HIGH MOLECULAR WEIGHT KININOGEN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE ANTIBODY; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS WASTAGE; HUMAN; NONHUMAN; RISK FACTOR; SPONTANEOUS ABORTION; STANDARDIZATION; THROMBOSIS; VEIN THROMBOSIS;

EID: 79551559094     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0147-5     Document Type: Article

References (27)

1. S Miyakis MD Lockshin T Atsumi, et al. 2006 International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome J Thromb Haemost 4 295 306 1:CAS:528: DC%2BD28XisVSjuro%3D 10.1111/j.1538-7836.2006.01753.x 16420554
2. M Berard R Chantome A Marcelli 1996 Boffa MC: Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 23 1369 74 1:STN:280:DyaK2s%2FgvFGisg%3D%3D
3. T Sugi J Katsunuma SI Izumi 1999 Prevalence and heterogeneity of antiphosphatidyl-ethanolamine antibodies in patients with recurrent early pregnancy losses Fertil Steril 71 1060 5 1:STN:280:DyaK1M3oslKmtw%3D%3D 10.1016/S0015-0282(99)00119-3 10360910 (Pubitemid 29252496)
4. JC Gris I Quere M Sanmarco, et al. 2000 Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early fetal loss Thromb Haemost 84 228 36 1:CAS:528:DC%2BD3cXmt1OnsbY%3D 10959694
5. M Sanmarco MC Alessi JR Harle, et al. 2001 Antibodies to phosphatidylethanolamine as the only antiphospholipid antibodies found in patients with unexplained thromboses Thromb Haemost 85 800 5 1:CAS:528:DC%2BD3MXjslyktL4%3D 11372671
6. T Sugi J Katsunuma SI Izumi, et al. 1999 Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses Fertil Steril 71 1060 5 1:STN:280:DyaK1M3oslKmtw%3D%3D 10.1016/S0015-0282(99)00119-3 10360910 (Pubitemid 29252496)
7. T Sugi H Matsubayashi A Inomo, et al. 2004 Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss Obstet Gynaecol Res 30 326 32 10.1111/j.1447-0756.2004.00206.x (Pubitemid 39108450)
8. M Sanmarco S Gayet MC Alessi, et al. 2007 Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies Thromb Haemost 97 949 54 1:CAS:528: DC%2BD2sXmvVWku70%3D 17549297
9. J Hirmerova Z Ulcova-Gallova J Seidlerova, et al. 2010 Laboratory evaluation of antiphospholipid antibodies in patients with venous thromboembolism Clin Appl Thromb Hemost 16 318 25 1:STN:280: DC%2BC3crgtVSjsA%3D%3D 10.1177/1076029608331228 19221100
10. MD Smirnov DA Ford CT Esmon NL Esmon 1999 The effect of membrane composition on the hemostatic balance Biochemistry 23 3591 8 10.1021/bi982538b (Pubitemid 29149477)
11. T Tsuda H Yoshimura N Hamasaki 2006 Effect of phosphatidylcholine, phosphatidylethanolamine and lysophosphatidylcholine on the activated factor X-prothrombin system Blood Coagul Fibrinolysis 17 465 9 1:CAS:528: DC%2BD28XotVWlu7g%3D 10.1097/01.mbc.0000240919.72930.ee 16905950 (Pubitemid 44231692)
12. FJ Walker 1981 Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation J Biol Chem 256 11128 31 1:CAS:528:DyaL3MXmtVWgsLs%3D 6457049
13. EA Norstrøm M Steen S Tran B Dahlbäck 2003 Importance of protein S and phospholipid for activated protein C-mediated cleavages in factor Va J Biol Chem 278 24904 11 10.1074/jbc.M303829200 12707283 (Pubitemid 37548650)
14. •• Li Z, Wells CW, North PE, et al.: Phosphatidylethanolamine at the Luminal Endothelial Surface: Implications in Hemostasis and Thrombotic Autoimmunity. Clin Appl Thromb Hemost. 2009 Nov 10 (Epub ahead of print). The authors used duramycin, a PE-binding probe, and immunohistochemistry to estimate the distribution profile of PE on rat aortic arch. Their findings provide the evidence to support a physical presence of PE at the blood-endothelium interface and its susceptibility to aPE binding.
15. PF Neuenschwander E Bianco-Fisher AR Rezaie JH Morrissey 1995 Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine Biochemistry 34 13988 93 1:CAS:528:DyaK2MXos1Wmt7w%3D 10.1021/bi00043a004 7577996
16. EF Smeets P Comfurius EM Bevers RF Zwaal 1996 Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles Thromb Res 81 419 26 1:CAS:528:DyaK28XhsVCgtro%3D 10.1016/0049-3848(96) 00014-X 8907291 (Pubitemid 26100412)
17. P Baumgärtner M Geiger S Zieseniss, et al. 2007 Phosphatidylethanolamine critically supports internalization of cell-penetrating protein C inhibitor J Cell Biol 179 793 804 10.1083/jcb.200707165 18025309 (Pubitemid 350146262)
18. J Rauch M Tannenbaum C Neville PR Fortin 1998 Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin Thromb Haemost 80 936 41 1:CAS:528:DyaK1cXotVSls78%3D 9869164
19. T Sugi JA Mclntyre 1996 Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies Thromb Haemost 76 354 60 1:CAS:528:DyaK28Xls1Wjuro%3D 8883270
20. T Sugi JA McIntyre 2001 Certain autoantibodies to phosphatidylethanolamine (aPE) recognize factor XI and prekallikrein independently or in addition to the kininogens J Autoimmun 17 207 14 1:STN:280:DC%2BD3MnmslGqtA%3D%3D 10.1006/jaut.2001.0543 11712858 (Pubitemid 33108756)
21. KA Drouvalakis RR Buchanan 1999 Microtitre plate and assay buffer alter detection of antiphosphatidylethanolamine antibodies in lupus anticoagulant positive plasma Thromb Res 94 205 12 1:CAS:528:DyaK1MXjtVKktLw%3D 10.1016/S0049-3848(98)00175-3 10336235 (Pubitemid 29238347)
22. M Berard MC Boffa 1997 Influence of the phosphatidylethanolamine (PE) and bovine serum origins on anti-PE antibody detection by ELISA Thromb Res 85 439 42 1:CAS:528:DyaK2sXhvVynt7g%3D 10.1016/S0049-3848(97)00032-7 9076901 (Pubitemid 27191731)
23. JA McIntyre DR Wagenknecht 2000 Anti-phosphatidylethanolamine (aPE) antibodies: a survey J Autoimmun 15 185 93 1:STN:280:DC%2BD3M7nvVWjtA%3D%3D 10.1006/jaut.2000.0425 10968907
24. • Sanmarco M: ELISA for antiphosphatidylethanolamine antibody detection: high impact of assay buffer on results. J Immunol Methods 2010; 358:9-16. This article documents the impact of the lipid content of the assay buffer on the results and provides significant help regarding standardization of aPE ELISA.
25. T Sugi JA McIntyre 1995 Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex Blood 86 3083 9 1:CAS:528:DyaK2MXos1ynsLk%3D 7579402
26. Y Tian P Jackson C Gunter, et al. 2006 Placental thrombosis and spontaneous fetal death in mice deficient in ethanolamine kinase 2 J Biol Chem 281 28438 49 1:CAS:528:DC%2BD28XpsFOqtr0%3D 10.1074/jbc.M605861200 16861741 (Pubitemid 44414557)
27. Matsubayashi H, Velayuthaprabhu S, Sugi T, et al.: Animal model for anti- phosphatidylethanolamine or anti-factor XII antibodies (aPE) with passive immunization [abstract 33]. Presented at the 13th International Congress on APL Antibodies. Galveston, TX; April 13-16, 2010.